T-knife Therapeutics Announces Four Upcoming Data Presentations on PRAME-Targeted TK-6302 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
— Posters will review product characterization and manufacturing data on T-knife's lead program, TK-6302, a supercharged PRAME T cell receptor therapy that is advancing towards the clinic, with the filing of a Clinical Trial Application planned in Q4 2025 — PRAME is a validated target and is expressed in cancers of the skin, uterus, ovaries, […]